Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Food Hypersensitivity | 11 | 2024 | 67 | 3.350 |
Why?
|
| Peanut Hypersensitivity | 8 | 2023 | 15 | 2.930 |
Why?
|
| Asthma | 12 | 2022 | 973 | 2.290 |
Why?
|
| Desensitization, Immunologic | 9 | 2023 | 37 | 2.170 |
Why?
|
| Tobacco Smoke Pollution | 4 | 2016 | 25 | 1.960 |
Why?
|
| Arachis | 6 | 2023 | 11 | 1.740 |
Why?
|
| Dust | 4 | 2017 | 26 | 1.660 |
Why?
|
| Allergens | 11 | 2024 | 181 | 1.130 |
Why?
|
| Environmental Exposure | 6 | 2017 | 321 | 1.090 |
Why?
|
| Anaphylaxis | 2 | 2023 | 33 | 1.000 |
Why?
|
| Hypersensitivity | 4 | 2021 | 158 | 0.990 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2022 | 47 | 0.970 |
Why?
|
| Insurance Claim Review | 1 | 2024 | 46 | 0.960 |
Why?
|
| Health Expenditures | 1 | 2024 | 91 | 0.880 |
Why?
|
| Hypersensitivity, Immediate | 3 | 2013 | 63 | 0.880 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2022 | 25 | 0.850 |
Why?
|
| Egg Hypersensitivity | 2 | 2019 | 4 | 0.810 |
Why?
|
| Child | 22 | 2024 | 7081 | 0.800 |
Why?
|
| Housing | 5 | 2015 | 43 | 0.800 |
Why?
|
| Child, Preschool | 17 | 2024 | 3671 | 0.780 |
Why?
|
| Allergy and Immunology | 1 | 2019 | 12 | 0.700 |
Why?
|
| Dermatitis, Atopic | 3 | 2024 | 55 | 0.630 |
Why?
|
| Poverty | 3 | 2016 | 179 | 0.610 |
Why?
|
| 2S Albumins, Plant | 1 | 2017 | 1 | 0.600 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 168 | 0.590 |
Why?
|
| Antigens, Plant | 1 | 2017 | 14 | 0.590 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 510 | 0.590 |
Why?
|
| Environmental Monitoring | 3 | 2014 | 74 | 0.560 |
Why?
|
| Glycoproteins | 2 | 2017 | 235 | 0.560 |
Why?
|
| Humans | 48 | 2024 | 88482 | 0.540 |
Why?
|
| Pandemics | 2 | 2021 | 760 | 0.540 |
Why?
|
| Microbiota | 2 | 2018 | 396 | 0.530 |
Why?
|
| Pediatrics | 1 | 2019 | 351 | 0.520 |
Why?
|
| Pyroglyphidae | 2 | 2013 | 14 | 0.480 |
Why?
|
| Eczema | 1 | 2014 | 7 | 0.480 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2014 | 51 | 0.450 |
Why?
|
| Dietary Supplements | 1 | 2014 | 129 | 0.440 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2013 | 81 | 0.440 |
Why?
|
| Air Pollution, Indoor | 4 | 2014 | 63 | 0.410 |
Why?
|
| Angioedema | 1 | 2011 | 4 | 0.400 |
Why?
|
| Bacteria | 1 | 2015 | 468 | 0.400 |
Why?
|
| Familial Mediterranean Fever | 1 | 2010 | 4 | 0.380 |
Why?
|
| Cryopyrin-Associated Periodic Syndromes | 1 | 2010 | 2 | 0.380 |
Why?
|
| Stomatitis, Aphthous | 1 | 2010 | 4 | 0.380 |
Why?
|
| United States | 11 | 2024 | 6877 | 0.380 |
Why?
|
| Pharyngitis | 1 | 2010 | 16 | 0.380 |
Why?
|
| Retrospective Studies | 7 | 2024 | 8869 | 0.370 |
Why?
|
| Models, Theoretical | 1 | 2012 | 489 | 0.350 |
Why?
|
| Smoking | 1 | 2013 | 618 | 0.340 |
Why?
|
| Administration, Oral | 5 | 2022 | 684 | 0.340 |
Why?
|
| Medicaid | 2 | 2022 | 228 | 0.320 |
Why?
|
| Infant | 6 | 2024 | 3113 | 0.310 |
Why?
|
| Female | 19 | 2024 | 45687 | 0.300 |
Why?
|
| Rhinitis, Allergic | 2 | 2019 | 45 | 0.280 |
Why?
|
| Adolescent | 11 | 2024 | 9141 | 0.270 |
Why?
|
| Immune Tolerance | 2 | 2019 | 338 | 0.260 |
Why?
|
| Male | 16 | 2024 | 41953 | 0.250 |
Why?
|
| Epinephrine | 2 | 2021 | 86 | 0.240 |
Why?
|
| Food Supply | 2 | 2021 | 29 | 0.240 |
Why?
|
| Health Resources | 1 | 2024 | 82 | 0.230 |
Why?
|
| Air Microbiology | 2 | 2014 | 5 | 0.230 |
Why?
|
| Double-Blind Method | 3 | 2022 | 1712 | 0.220 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1688 | 0.220 |
Why?
|
| Fungi | 2 | 2014 | 66 | 0.220 |
Why?
|
| Skin Tests | 1 | 2022 | 44 | 0.210 |
Why?
|
| Food | 2 | 2022 | 86 | 0.210 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 577 | 0.210 |
Why?
|
| Vocabulary, Controlled | 1 | 2022 | 13 | 0.210 |
Why?
|
| Albuterol | 1 | 2022 | 35 | 0.210 |
Why?
|
| Early Diagnosis | 1 | 2022 | 122 | 0.200 |
Why?
|
| Food Assistance | 1 | 2021 | 7 | 0.200 |
Why?
|
| Probiotics | 2 | 2024 | 86 | 0.200 |
Why?
|
| Data Collection | 1 | 2023 | 374 | 0.200 |
Why?
|
| Kansas | 3 | 2016 | 6 | 0.190 |
Why?
|
| Immunologic Factors | 1 | 2022 | 170 | 0.190 |
Why?
|
| Case-Control Studies | 2 | 2017 | 1848 | 0.190 |
Why?
|
| Comorbidity | 1 | 2024 | 947 | 0.180 |
Why?
|
| Terminology as Topic | 2 | 2018 | 219 | 0.180 |
Why?
|
| Skin | 1 | 2024 | 580 | 0.180 |
Why?
|
| Machine Learning | 1 | 2022 | 242 | 0.180 |
Why?
|
| Prevalence | 2 | 2014 | 1248 | 0.180 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 34 | 0.180 |
Why?
|
| Journal Impact Factor | 1 | 2019 | 15 | 0.180 |
Why?
|
| Egg Proteins, Dietary | 1 | 2019 | 1 | 0.170 |
Why?
|
| Virus Diseases | 1 | 2020 | 97 | 0.170 |
Why?
|
| Allergists | 1 | 2018 | 4 | 0.170 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 107 | 0.170 |
Why?
|
| Prebiotics | 1 | 2018 | 8 | 0.170 |
Why?
|
| Fatty Acids, Volatile | 1 | 2018 | 32 | 0.160 |
Why?
|
| Hospitalization | 1 | 2024 | 869 | 0.160 |
Why?
|
| Infant, Newborn | 1 | 2024 | 2441 | 0.160 |
Why?
|
| Plant Proteins | 1 | 2018 | 134 | 0.150 |
Why?
|
| Collagen Type V | 1 | 2017 | 2 | 0.150 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2017 | 8 | 0.150 |
Why?
|
| Skin Abnormalities | 1 | 2017 | 11 | 0.150 |
Why?
|
| Eye Abnormalities | 1 | 2017 | 41 | 0.150 |
Why?
|
| Cross Reactions | 1 | 2017 | 109 | 0.150 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 21 | 0.140 |
Why?
|
| Joint Instability | 1 | 2017 | 82 | 0.140 |
Why?
|
| Biological Products | 1 | 2018 | 147 | 0.140 |
Why?
|
| Young Adult | 3 | 2024 | 6193 | 0.140 |
Why?
|
| Disease Progression | 2 | 2020 | 1489 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2014 | 685 | 0.130 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 52 | 0.130 |
Why?
|
| Genes, Bacterial | 1 | 2015 | 198 | 0.120 |
Why?
|
| Health Policy | 1 | 2016 | 185 | 0.120 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2015 | 247 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 85 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2017 | 865 | 0.120 |
Why?
|
| Urban Population | 1 | 2015 | 223 | 0.120 |
Why?
|
| Fish Oils | 1 | 2014 | 14 | 0.120 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2014 | 111 | 0.120 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 101 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 525 | 0.120 |
Why?
|
| Docosahexaenoic Acids | 1 | 2014 | 32 | 0.110 |
Why?
|
| Antigens, Dermatophagoides | 2 | 2013 | 11 | 0.110 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 145 | 0.110 |
Why?
|
| Food Contamination | 1 | 2012 | 32 | 0.110 |
Why?
|
| Disease Reservoirs | 1 | 2012 | 22 | 0.110 |
Why?
|
| Immune System | 1 | 2013 | 97 | 0.110 |
Why?
|
| Risk | 1 | 2014 | 660 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 248 | 0.100 |
Why?
|
| Adult | 8 | 2024 | 26303 | 0.100 |
Why?
|
| Complement C1 Inactivator Proteins | 1 | 2011 | 1 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2016 | 655 | 0.100 |
Why?
|
| Angioedemas, Hereditary | 1 | 2011 | 2 | 0.100 |
Why?
|
| Complement C4 | 1 | 2011 | 10 | 0.100 |
Why?
|
| Urticaria | 1 | 2011 | 14 | 0.100 |
Why?
|
| Animals | 6 | 2024 | 27203 | 0.100 |
Why?
|
| Air Pollutants | 1 | 2013 | 92 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 863 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 477 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2014 | 536 | 0.090 |
Why?
|
| Middle Aged | 5 | 2024 | 25649 | 0.090 |
Why?
|
| Phylogeny | 1 | 2015 | 1170 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 837 | 0.090 |
Why?
|
| Environmental Restoration and Remediation | 1 | 2009 | 6 | 0.090 |
Why?
|
| Health Maintenance Organizations | 1 | 2009 | 20 | 0.080 |
Why?
|
| Family Practice | 1 | 2009 | 85 | 0.080 |
Why?
|
| Aged | 3 | 2024 | 18904 | 0.080 |
Why?
|
| Pregnancy | 1 | 2014 | 2995 | 0.070 |
Why?
|
| Patient Education as Topic | 3 | 2020 | 356 | 0.070 |
Why?
|
| Electric Countershock | 1 | 2006 | 51 | 0.070 |
Why?
|
| Ventricular Fibrillation | 1 | 2006 | 66 | 0.070 |
Why?
|
| Bezoars | 1 | 2005 | 4 | 0.070 |
Why?
|
| Rubber | 1 | 2005 | 6 | 0.070 |
Why?
|
| Pica | 1 | 2005 | 14 | 0.070 |
Why?
|
| Tachycardia, Ventricular | 1 | 2006 | 120 | 0.060 |
Why?
|
| Intestinal Obstruction | 1 | 2005 | 88 | 0.060 |
Why?
|
| Defibrillators, Implantable | 1 | 2006 | 140 | 0.060 |
Why?
|
| Administration, Topical | 1 | 2023 | 96 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2023 | 60 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2006 | 335 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2023 | 93 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 175 | 0.050 |
Why?
|
| Iowa | 1 | 2022 | 35 | 0.050 |
Why?
|
| Prescriptions | 1 | 2022 | 22 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 412 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2023 | 111 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2021 | 83 | 0.050 |
Why?
|
| Genome, Viral | 1 | 2020 | 78 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 133 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 2322 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2022 | 383 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2020 | 79 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2018 | 42 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 272 | 0.040 |
Why?
|
| beta-Thalassemia | 1 | 1997 | 6 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 274 | 0.040 |
Why?
|
| Joints | 1 | 2017 | 32 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 149 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 1997 | 235 | 0.040 |
Why?
|
| Face | 1 | 2017 | 116 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2017 | 273 | 0.030 |
Why?
|
| Social Class | 1 | 2016 | 134 | 0.030 |
Why?
|
| Risk Factors | 3 | 2014 | 5439 | 0.030 |
Why?
|
| Hepatitis C | 1 | 1997 | 219 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2014 | 43 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 52 | 0.030 |
Why?
|
| Mutation | 2 | 2017 | 4097 | 0.030 |
Why?
|
| Missouri | 1 | 2014 | 19 | 0.030 |
Why?
|
| Genes, rRNA | 1 | 2014 | 7 | 0.030 |
Why?
|
| Genes, Fungal | 1 | 2014 | 58 | 0.030 |
Why?
|
| Exome | 1 | 2014 | 127 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1860 | 0.030 |
Why?
|
| Cities | 1 | 2014 | 43 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 478 | 0.030 |
Why?
|
| Arthropod Proteins | 1 | 2013 | 8 | 0.030 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 491 | 0.030 |
Why?
|
| United States Environmental Protection Agency | 1 | 2012 | 5 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 1311 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 2013 | 88 | 0.030 |
Why?
|
| DNA, Fungal | 1 | 2012 | 58 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2013 | 141 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 230 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 1129 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 302 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1038 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1842 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 3653 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2833 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 927 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 863 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1586 | 0.020 |
Why?
|
| Air Conditioning | 1 | 2009 | 6 | 0.020 |
Why?
|
| Genome, Human | 1 | 2014 | 767 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2009 | 46 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 150 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2009 | 53 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2009 | 160 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 179 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2009 | 235 | 0.020 |
Why?
|
| Interior Design and Furnishings | 1 | 2005 | 1 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2399 | 0.020 |
Why?
|
| Illinois | 1 | 2006 | 465 | 0.020 |
Why?
|
| Registries | 1 | 2009 | 754 | 0.020 |
Why?
|
| Boutonneuse Fever | 1 | 1983 | 1 | 0.010 |
Why?
|
| Rickettsiaceae Infections | 1 | 1983 | 2 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1983 | 71 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 1881 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 2285 | 0.010 |
Why?
|
| Prognosis | 2 | 2006 | 3749 | 0.010 |
Why?
|
| Siderosis | 1 | 1997 | 2 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1997 | 74 | 0.010 |
Why?
|
| Iron | 1 | 1997 | 166 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2006 | 6713 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1020 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 994 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1997 | 948 | 0.010 |
Why?
|
| Liver | 1 | 1997 | 1241 | 0.010 |
Why?
|
| Time Factors | 1 | 1997 | 5309 | 0.000 |
Why?
|